Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Gyor – page 12

149 clinical trials in Gyor, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gyor at a glance
149
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

149 trials in Gyor

Open in trial search

Small cell lung cancer limited stage

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MK-0482
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage I+1

Not recruiting

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Gyor

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple cancer types, including breast, lung, and prostate cancer. Studies are evaluating novel combination therapies and immunotherapy approaches.

  • Advanced Breast Cancer Treatments
  • Non-Small Cell Lung Cancer Therapy
  • Prostate Cancer Interventions

Research includes targeted therapies for hormone receptor-positive cancers and new treatment combinations for metastatic disease.

02 Cardiovascular and Renal Studies

Research centered on treating chronic kidney disease and preventing cardiovascular events. Studies evaluating new therapeutic approaches for blood pressure management.

  • Kidney Disease Management
  • Stroke Prevention
  • Atrial Fibrillation Treatment

Focus on innovative combinations of medications to improve patient outcomes in cardiovascular conditions.

03 Immunology and Inflammatory Conditions

Clinical investigations examining treatments for autoimmune disorders and inflammatory conditions, including multiple sclerosis and ulcerative colitis.

  • Multiple Sclerosis Therapies
  • Inflammatory Bowel Disease
  • Immune Thrombocytopenia

Testing novel therapeutic approaches to modify immune response and reduce inflammation.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.